Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abvc Biopharma (ABVC) Profit After Tax (2016 - 2025)

Abvc Biopharma (ABVC) has disclosed Profit After Tax for 13 consecutive years, with -$4.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Profit After Tax fell 270.62% year-over-year to -$4.0 million, compared with a TTM value of -$9.4 million through Dec 2025, down 141.63%, and an annual FY2025 reading of -$8.4 million, down 59.29% over the prior year.
  • Profit After Tax was -$4.0 million for Q4 2025 at Abvc Biopharma, down from -$2.1 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $1.1 million in Q3 2024 and bottomed at -$7.7 million in Q4 2021.
  • Average Profit After Tax over 5 years is -$2.5 million, with a median of -$2.1 million recorded in 2021.
  • Peak annual rise in Profit After Tax hit 132.63% in 2024, while the deepest fall reached 424.17% in 2024.
  • Year by year, Profit After Tax stood at -$7.7 million in 2021, then soared by 38.31% to -$4.8 million in 2022, then surged by 95.63% to -$207515.0 in 2023, then tumbled by 424.17% to -$1.1 million in 2024, then tumbled by 270.62% to -$4.0 million in 2025.
  • Business Quant data shows Profit After Tax for ABVC at -$4.0 million in Q4 2025, -$2.1 million in Q3 2025, and -$2.4 million in Q2 2025.